Trials / Unknown
UnknownNCT04015635
The Role of the Immune and Inflammatory Systems in Hypertension
A Study of the Roles of the Immune and Inflammatory Systems in Hypertension
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 160 (estimated)
- Sponsor
- University of Glasgow · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To define the cytokine and cellular immune signature of primary hypertension. Cross sectional clinical/laboratory study.
Detailed description
Experimental data show the presence of immune and inflammatory systems dysregulation in hypertension. Understanding of the inflammatory and immune nature of hypertension is currently based on studies in rodent models of hypertension, but is supported by human epidemiological and genome wide association studies (GWAS) studies. It is now essential to identify key checkpoints and inflammatory mechanism(s) involved in human hypertension in comprehensive and sufficiently powered studies, which will then be able to guide subsequent in-depth hypothesis-driven mechanistic studies. This approach may provide the basis for future randomized clinical trials (RCTs). To define the relationships and predictive value of the immune signature of hypertension and clinical phenotypes of hypertension : * Predictive value of immune signature for blood pressure parameters measured by ambulatory blood pressure measurements (ABPM) * Predictive value of immune signature for endothelial function assessed by Endo-PAT2000 and flow mediated dilatation (FMD) both complementary non-invasive techniques. * Predictive value of immune signature for vascular stiffness and central pressure assessed by SphygmoCor * Predictive value of immune signature for renal function parameters * Predictive value of immune signature for cognitive function. To define genetic determinants of immune signature of hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | None involved | NO intervention |
Timeline
- Start date
- 2019-05-07
- Primary completion
- 2021-09-01
- Completion
- 2021-09-01
- First posted
- 2019-07-11
- Last updated
- 2021-05-14
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04015635. Inclusion in this directory is not an endorsement.